Hospital Pharmacy

Rotterdam, Netherlands

Hospital Pharmacy

Rotterdam, Netherlands

Time filter

Source Type

In 2015, the top five companies comprising AmerisourceBergen Corporation, DB Schenker, UPS, FedEx, and DHL held the dominant share of 31% in the global biopharmaceutical logistics market. Aiming at expanding their regional footprint, several of the established players are investing in construction of facilities across emerging nations. Also to make their foothold stronger, the leading market players are providing user-friendly shipping, e-commerce, logistics management, and visibility tools. Considering the strategies undertaken by the players in a dynamic business environment, experts predict positive outlook for the global biopharmaceutical logistics market. According to TMR, the global biopharmaceutical logistics market will reach US$120.7 bn, exhibiting a CAGR of 6.2% between 2016 and 2024. In 2015, the market was valued at US$70.9 bn. Based on type, the market can be bifurcated into cold chain logistics and non-cold chain logistics. Of these, the non-cold chain logistics segment held the leading share of 80% in the global market in 2015. Regionally, North America emerged dominant with a share of 32.9% in the global market in 2015. Sound Know-how of Logistics Providers to Create Growth Opportunities for Market Many logistics providers are making positive strides in the market and are seen enhancing their regional and local presence and expertise. These companies have sound knowledge and a strong network of local contacts. The sound know-hows of logistics providers can help in reducing challenges for pharmaceutical companies especially those running critical trials in emerging markets, or shipping in politically and legally difficult zones. This is also driving the expansion of the global biopharmaceutical logistics market. Cold chain carriers have considerably invested in devices built into refrigeration units to monitor location and temperature aimed at meeting industry demands. The technology has also enabled drug manufacturers to access relevant data in real time. It also offers increased visibility and the opportunity to prevent or mitigate loss of a critical shipment. The advent of the technology, coupled with recent innovations in packaging has provided significant impetus to the biopharmaceutical logistics market. Also with the increasing manufacture and usage biological drugs, the demand for biopharmaceutical logistics is expected to get spurred. Inquire for a sample copy of this Report @ http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=23858 On the downside, the cost of transporting biopharmaceuticals, especially the ones that are temperature sensitive and need rapid delivery to destinations, is very expensive. As with companies opting for air transport, they claim air shipping to cost considerably higher than transporting by sea. As fast shipping of highly temperature sensitive biopharmaceuticals is only possible by air transport, it has emerged as a major challenge for the market players. Also regulatory concerns and region-specific temperature control challenges are posing threat to the global biopharmaceutical logistics market. Advent of Targeted Therapies to Pave Way for Growth The world of medicine has witnessed a new wave of targeted therapies, which are designed as per the treatment needs of a particular patient. Therefore, the demand for targeted logistics solutions is expected to gain pace as therapies and drugs evolve to meet demands of more targeted approach. These developments are likely to help the market emerge out of the aforementioned challenges. Besides this, advent of innovative solutions aimed at mitigating challenges in clinical trial supply chain is likely to aid the market's expansion in the coming years. Information that this review is based on is derived from a TMR report, titled "Biopharmaceutical Logistics Market (Type - Cold Chain Logistics and Non-cold Chain Logistics; Mode of Transportation - Air Shipping, Sea Shipping, Road Shipping, and Rail Shipping; Service -Transportation and Warehousing) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024." The report segments the global biopharmaceutical logistics market as: Pharmerging Market (Product Type - Pharmaceuticals (Branded Prescription Drugs, Generic Drugs (Branded Generics, Unbranded Generics, and OTC Drugs) and Healthcare (Medical Devices, Diagnostic Instruments, and IT and Record Management); Economic Growth Levels - Tier - 1, Tier - 2, and Tier - 3; Indications - Lifestyle Diseases, Cancer and Autoimmune Diseases, and Infectious Diseases; Distribution Channel - Hospitals, Clinics, Retail Pharmacies, E-commerce, and Drug Stores) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024 Pharmacy Repackaging Systems Market (Product - Blister Card/Compliance Packaging Systems (Multi Dose Blister Card Packaging Systems, Single Dose Blister Card Packaging Systems, Heat Sealers, and Deblisters Machines), Pouch Packaging Automation Systems (Automatic Tablet Packager and Pouch Verification System), Bottle Filling/ Pill Counting Automation Systems (Automated Bottle Filler and Pill Counter), and Liquid Medication Packaging Systems (Oral Liquid Filling Syrup and Automated Vial Filling Pump) ; End User - Retail/Community Pharmacy, Hospital Pharmacy, Long-term Care (LTC) Pharmacies, and Mail Order Pharmacies) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024 Transparency Market Research (TMR) is a U.S. based provider of syndicated research, customized research, and consulting services. TMR's global and regional market intelligence coverage includes industries such as pharmaceutical, chemicals and materials, technology and media, food and beverages, and consumer goods, among others. Each TMR research report provides clients with a 360-degree view of the market with statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.


In 2015, the top five companies comprising AmerisourceBergen Corporation, DB Schenker, UPS, FedEx, and DHL held the dominant share of 31% in the global biopharmaceutical logistics market. Aiming at expanding their regional footprint, several of the established players are investing in construction of facilities across emerging nations. Also to make their foothold stronger, the leading market players are providing user-friendly shipping, e-commerce, logistics management, and visibility tools. Considering the strategies undertaken by the players in a dynamic business environment, experts predict positive outlook for the global biopharmaceutical logistics market. According to TMR, the global biopharmaceutical logistics market will reach US$120.7 bn, exhibiting a CAGR of 6.2% between 2016 and 2024. In 2015, the market was valued at US$70.9 bn. Based on type, the market can be bifurcated into cold chain logistics and non-cold chain logistics. Of these, the non-cold chain logistics segment held the leading share of 80% in the global market in 2015. Regionally, North America emerged dominant with a share of 32.9% in the global market in 2015. Sound Know-how of Logistics Providers to Create Growth Opportunities for Market Many logistics providers are making positive strides in the market and are seen enhancing their regional and local presence and expertise. These companies have sound knowledge and a strong network of local contacts. The sound know-hows of logistics providers can help in reducing challenges for pharmaceutical companies especially those running critical trials in emerging markets, or shipping in politically and legally difficult zones. This is also driving the expansion of the global biopharmaceutical logistics market. Cold chain carriers have considerably invested in devices built into refrigeration units to monitor location and temperature aimed at meeting industry demands. The technology has also enabled drug manufacturers to access relevant data in real time. It also offers increased visibility and the opportunity to prevent or mitigate loss of a critical shipment. The advent of the technology, coupled with recent innovations in packaging has provided significant impetus to the biopharmaceutical logistics market. Also with the increasing manufacture and usage biological drugs, the demand for biopharmaceutical logistics is expected to get spurred. Inquire for a sample copy of this Report @ http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=23858 On the downside, the cost of transporting biopharmaceuticals, especially the ones that are temperature sensitive and need rapid delivery to destinations, is very expensive. As with companies opting for air transport, they claim air shipping to cost considerably higher than transporting by sea. As fast shipping of highly temperature sensitive biopharmaceuticals is only possible by air transport, it has emerged as a major challenge for the market players. Also regulatory concerns and region-specific temperature control challenges are posing threat to the global biopharmaceutical logistics market. Advent of Targeted Therapies to Pave Way for Growth The world of medicine has witnessed a new wave of targeted therapies, which are designed as per the treatment needs of a particular patient. Therefore, the demand for targeted logistics solutions is expected to gain pace as therapies and drugs evolve to meet demands of more targeted approach. These developments are likely to help the market emerge out of the aforementioned challenges. Besides this, advent of innovative solutions aimed at mitigating challenges in clinical trial supply chain is likely to aid the market's expansion in the coming years. Information that this review is based on is derived from a TMR report, titled "Biopharmaceutical Logistics Market (Type - Cold Chain Logistics and Non-cold Chain Logistics; Mode of Transportation - Air Shipping, Sea Shipping, Road Shipping, and Rail Shipping; Service -Transportation and Warehousing) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024." The report segments the global biopharmaceutical logistics market as: Pharmerging Market (Product Type - Pharmaceuticals (Branded Prescription Drugs, Generic Drugs (Branded Generics, Unbranded Generics, and OTC Drugs) and Healthcare (Medical Devices, Diagnostic Instruments, and IT and Record Management); Economic Growth Levels - Tier - 1, Tier - 2, and Tier - 3; Indications - Lifestyle Diseases, Cancer and Autoimmune Diseases, and Infectious Diseases; Distribution Channel - Hospitals, Clinics, Retail Pharmacies, E-commerce, and Drug Stores) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024 Pharmacy Repackaging Systems Market (Product - Blister Card/Compliance Packaging Systems (Multi Dose Blister Card Packaging Systems, Single Dose Blister Card Packaging Systems, Heat Sealers, and Deblisters Machines), Pouch Packaging Automation Systems (Automatic Tablet Packager and Pouch Verification System), Bottle Filling/ Pill Counting Automation Systems (Automated Bottle Filler and Pill Counter), and Liquid Medication Packaging Systems (Oral Liquid Filling Syrup and Automated Vial Filling Pump) ; End User - Retail/Community Pharmacy, Hospital Pharmacy, Long-term Care (LTC) Pharmacies, and Mail Order Pharmacies) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024 Transparency Market Research (TMR) is a U.S. based provider of syndicated research, customized research, and consulting services. TMR's global and regional market intelligence coverage includes industries such as pharmaceutical, chemicals and materials, technology and media, food and beverages, and consumer goods, among others. Each TMR research report provides clients with a 360-degree view of the market with statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.


Receive press releases from iHealthcareAnalyst, Inc.: By Email Psoriasis Treatment Market by Drug Classes, Therapies, Distribution Channel and Forecast to 2021, Upcoming Report by iHealthcareAnalyst, Inc. Psoriasis Treatment Market by Drug Class (Interleukin Blockers, TNF Inhibitors, Vitamin D Analogues or Combinations, Others), Therapy Type (Systemic Therapeutic Drugs, Topical Therapeutic Drugs, Combinations, Others), Distribution Channel (Hospital Pharmacy, Online Sales, Retail Pharmacy, Others) and Forecast 2017-2021. Maryland Heights, MO, April 23, 2017 --( Browse Psoriasis Treatment Market by Drug Class (Interleukin Blockers, TNF Inhibitors, Vitamin D Analogues or Combinations, Others), Therapy Type (Systemic Therapeutic Drugs, Topical Therapeutic Drugs, Combinations, Others), Distribution Channel (Hospital Pharmacy, Online Sales, Retail Pharmacy, Others) and Forecast 2017-2021 at https://www.ihealthcareanalyst.com/report/psoriasis-treatment-market/ The global psoriasis treatment market segmentation is based on drug class (interleukin blockers, TNF inhibitors, vitamin d analogues or combinations, others), therapy type (systemic therapeutic drugs, topical therapeutic drugs, combinations, others), distribution channel (hospital pharmacy, online sales, retail pharmacy, others). The global psoriasis treatment market report provides market size (Revenue USD Million 2014 to 2021), market share, trends and forecasts growth trends (CAGR%, 2017 to 2021). The global psoriasis treatment market research report is further segmented by geography into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World. The global psoriasis treatment market report also provides the detailed market landscape (market drivers, restraints, opportunities), market attractiveness analysis and also tracks the major competitors operating in the market by company overview, financial snapshot, key products, technologies and services offered, market share analysis and recent trends in the global market. Major players operating in the global psoriasis treatment market and profiled in this report include AbbVie, Inc., Amgen, Inc., AstraZeneca, Biogen, Eli Lilly & Company, Johnson & Johnson, LEO Pharma A/S, Merck & Co., Inc., Novartis AG, and Pfizer, Inc. 1. Drug Class 1.1. Interleukin Blockers 1.2. TNF Inhibitors 1.3. Vitamin D Analogues or Combinations 1.4. Others 2. Therapy Type 2.1. Systemic Therapeutic Drugs 2.2. Topical Therapeutic Drugs 2.3. Combinations 2.4. Others 3. Distribution Channel 3.1. Hospital Pharmacy 3.2. Online Sales 3.3. Retail Pharmacy 3.4. Others 4. Geography (Region, Country) 4.1. North America (U.S., Canada) 4.2. Latin America (Brazil, Mexico, Rest of LA) 4.3. Europe (U.K., Germany, France, Italy, Spain, Rest of EU) 4.4. Asia Pacific (Japan, China, India, Rest of APAC) 4.5. Rest of the World 5. Company Profiles 5.1. AbbVie, Inc. 5.2. Amgen, Inc. 5.3. AstraZeneca 5.4. Biogen 5.5. Eli Lilly & Company 5.6. Johnson & Johnson 5.7. LEO Pharma A/S 5.8. Merck & Co., Inc. 5.9. Novartis AG 5.10. Pfizer, Inc. To request Table of Contents and Sample Pages of this report visit: https://www.ihealthcareanalyst.com/report/psoriasis-treatment-market/ About Us iHealthcareAnalyst, Inc. is a global healthcare market research and consulting company providing market analysis, and competitive intelligence services to global clients. The company publishes syndicate, custom and consulting grade healthcare reports covering animal healthcare, biotechnology, clinical diagnostics, healthcare informatics, healthcare services, medical devices, medical equipment, and pharmaceuticals. In addition to multi-client studies, we offer creative consulting services and conduct proprietary single-client assignments targeted at client’s specific business objectives, information needs, time frame and budget. Please contact us to receive a proposal for a proprietary single-client study. Contact Us iHealthcareAnalyst, Inc. 2109, Mckelvey Hill Drive Maryland Heights, MO 63043 United States Email: sales@ihealthcareanalyst.com Website: https://www.ihealthcareanalyst.com Maryland Heights, MO, April 23, 2017 --( PR.com )-- Psoriasis is a long-lasting autoimmune disease which is characterized by patches of abnormal skin. It is often diagnosed or at least suspected on the basis of its appearance and distribution. There is no cure for psoriasis, however, various treatments can help control the symptoms. Topical treatments such as form of lotions, foams, creams, ointments, gels, and shampoos containing steroids, tar preparations, and calcium- modulating drugs are very useful because they are relatively safe, fairly effective, and can be applied directly to the affected skin. Most oral medications act by targeting portions of the immune system. Phototherapy or light therapy, involves exposing the skin to ultraviolet light on a regular basis and under medical supervision. Biologic drugs are usually prescribed for moderate to severe psoriasis and psoriatic arthritis that has not responded to other treatments. Treatments for more advanced psoriasis include narrow-band ultraviolet B (UVB) light, psoralen with ultraviolet A (UVA) light retinoids (isotretinoin [Accutane, Claravis], acitretin [Soriatane]), methotrexate (particularly for arthritis), cyclosporine (Neoral, Sandimmune), infliximab (Remicade), etanercept (Enbrel), adalimumab (Humira), apremilast (Otezla), and secukinumab (Cosentyx). Currently, calcineurin inhibitors such as tacrolimus (Prograf) and pimecrolimus (Elidel) are approved only for the treatment of atopic dermatitis. Vitamin D analogues such as Calcipotriene (Dovonex) slow down the growth of skin cells.Browse Psoriasis Treatment Market by Drug Class (Interleukin Blockers, TNF Inhibitors, Vitamin D Analogues or Combinations, Others), Therapy Type (Systemic Therapeutic Drugs, Topical Therapeutic Drugs, Combinations, Others), Distribution Channel (Hospital Pharmacy, Online Sales, Retail Pharmacy, Others) and Forecast 2017-2021 at https://www.ihealthcareanalyst.com/report/psoriasis-treatment-market/The global psoriasis treatment market segmentation is based on drug class (interleukin blockers, TNF inhibitors, vitamin d analogues or combinations, others), therapy type (systemic therapeutic drugs, topical therapeutic drugs, combinations, others), distribution channel (hospital pharmacy, online sales, retail pharmacy, others).The global psoriasis treatment market report provides market size (Revenue USD Million 2014 to 2021), market share, trends and forecasts growth trends (CAGR%, 2017 to 2021). The global psoriasis treatment market research report is further segmented by geography into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World. The global psoriasis treatment market report also provides the detailed market landscape (market drivers, restraints, opportunities), market attractiveness analysis and also tracks the major competitors operating in the market by company overview, financial snapshot, key products, technologies and services offered, market share analysis and recent trends in the global market.Major players operating in the global psoriasis treatment market and profiled in this report include AbbVie, Inc., Amgen, Inc., AstraZeneca, Biogen, Eli Lilly & Company, Johnson & Johnson, LEO Pharma A/S, Merck & Co., Inc., Novartis AG, and Pfizer, Inc.1. Drug Class1.1. Interleukin Blockers1.2. TNF Inhibitors1.3. Vitamin D Analogues or Combinations1.4. Others2. Therapy Type2.1. Systemic Therapeutic Drugs2.2. Topical Therapeutic Drugs2.3. Combinations2.4. Others3. Distribution Channel3.1. Hospital Pharmacy3.2. Online Sales3.3. Retail Pharmacy3.4. Others4. Geography (Region, Country)4.1. North America (U.S., Canada)4.2. Latin America (Brazil, Mexico, Rest of LA)4.3. Europe (U.K., Germany, France, Italy, Spain, Rest of EU)4.4. Asia Pacific (Japan, China, India, Rest of APAC)4.5. Rest of the World5. Company Profiles5.1. AbbVie, Inc.5.2. Amgen, Inc.5.3. AstraZeneca5.4. Biogen5.5. Eli Lilly & Company5.6. Johnson & Johnson5.7. LEO Pharma A/S5.8. Merck & Co., Inc.5.9. Novartis AG5.10. Pfizer, Inc.To request Table of Contents and Sample Pages of this report visit: https://www.ihealthcareanalyst.com/report/psoriasis-treatment-market/About UsiHealthcareAnalyst, Inc. is a global healthcare market research and consulting company providing market analysis, and competitive intelligence services to global clients. The company publishes syndicate, custom and consulting grade healthcare reports covering animal healthcare, biotechnology, clinical diagnostics, healthcare informatics, healthcare services, medical devices, medical equipment, and pharmaceuticals.In addition to multi-client studies, we offer creative consulting services and conduct proprietary single-client assignments targeted at client’s specific business objectives, information needs, time frame and budget. Please contact us to receive a proposal for a proprietary single-client study.Contact UsiHealthcareAnalyst, Inc.2109, Mckelvey Hill DriveMaryland Heights, MO 63043United StatesEmail: sales@ihealthcareanalyst.comWebsite: https://www.ihealthcareanalyst.com Click here to view the list of recent Press Releases from iHealthcareAnalyst, Inc.


— This report studies sales (consumption) of Clinical Information System in Global market, especially in United States, China, Europe and Japan, focuses on top players in these regions/countries, with sales, price, revenue and market share for each player in these regions, covering Market Segment by Regions, this report splits Global into several key Regions, with sales (consumption), revenue, market share and growth rate of Clinical Information System in these regions, from 2011 to 2021 (forecast), like Split by product Types, with sales, revenue, price and gross margin, market share and growth rate of each type, can be divided into Cloud Based Web Based Split by applications, this report focuses on sales, market share and growth rate of Clinical Information System in each application, can be divided into Hospital Pharmacy Laboratory Global Clinical Information System Sales Market Report 2017 1 Clinical Information System Overview 1.1 Product Overview and Scope of Clinical Information System 1.2 Classification of Clinical Information System 1.2.1 Cloud Based 1.2.2 Web Based 1.3 Application of Clinical Information System 1.3.1 Hospital 1.3.2 Pharmacy 1.3.3 Laboratory 1.4 Clinical Information System Market by Regions 1.4.1 United States Status and Prospect (2012-2022) 1.4.2 China Status and Prospect (2012-2022) 1.4.3 Europe Status and Prospect (2012-2022) 1.4.4 Japan Status and Prospect (2012-2022) 1.4.5 Southeast Asia Status and Prospect (2012-2022) 1.4.6 India Status and Prospect (2012-2022) 1.5 Global Market Size (Value and Volume) of Clinical Information System (2012-2022) 1.5.1 Global Clinical Information System Sales and Growth Rate (2012-2022) 1.5.2 Global Clinical Information System Revenue and Growth Rate (2012-2022) 9 Global Clinical Information System Manufacturers Analysis 9.1 Clinicmaster 9.1.1 Company Basic Information, Manufacturing Base and Competitors 9.1.2 Clinical Information System Product Type, Application and Specification 9.1.2.1 Cloud Based 9.1.2.2 Web Based 9.1.3 Clinicmaster Clinical Information System Sales, Revenue, Price and Gross Margin (2012-2017) 9.1.4 Main Business/Business Overview 9.2 Quintiles 9.2.1 Company Basic Information, Manufacturing Base and Competitors 9.2.2 Clinical Information System Product Type, Application and Specification 9.2.2.1 Cloud Based 9.2.2.2 Web Based 9.2.3 Quintiles Clinical Information System Sales, Revenue, Price and Gross Margin (2012-2017) 9.2.4 Main Business/Business Overview 9.3 Accenture 9.3.1 Company Basic Information, Manufacturing Base and Competitors 9.3.2 Clinical Information System Product Type, Application and Specification 9.3.2.1 Cloud Based 9.3.2.2 Web Based 9.3.3 Accenture Clinical Information System Sales, Revenue, Price and Gross Margin (2012-2017) 9.3.4 Main Business/Business Overview 9.4 Allegro CTMS 9.4.1 Company Basic Information, Manufacturing Base and Competitors 9.4.2 Clinical Information System Product Type, Application and Specification 9.4.2.1 Cloud Based 9.4.2.2 Web Based 9.4.3 Allegro CTMS Clinical Information System Sales, Revenue, Price and Gross Margin (2012-2017) 9.4.4 Main Business/Business Overview 9.5 iMDsoft 9.5.1 Company Basic Information, Manufacturing Base and Competitors 9.5.2 Clinical Information System Product Type, Application and Specification 9.5.2.1 Cloud Based 9.5.2.2 Web Based 9.5.3 iMDsoft Clinical Information System Sales, Revenue, Price and Gross Margin (2012-2017) 9.5.4 Main Business/Business Overview 9.6 Surgical Information Systems 9.6.1 Company Basic Information, Manufacturing Base and Competitors 9.6.2 Clinical Information System Product Type, Application and Specification 9.6.2.1 Cloud Based 9.6.2.2 Web Based 9.6.3 Surgical Information Systems Clinical Information System Sales, Revenue, Price and Gross Margin (2012-2017) 9.6.4 Main Business/Business Overview For more information, please visit https://www.wiseguyreports.com/sample-request/928007-global-clinical-information-system-sales-market-report-2017


News Article | November 10, 2016
Site: www.PR.com

Global Drug Delivery Devices Market, By Product Type (Oral Solid, Liquid, Semi-Solid), Injectable, Topical, Pulmonary (MDI, DPI, Nebulizers), Nasal, Ocular, Implantable, Transmucosal), By End-User (Hospitals, Clinics, Home Healthcare, Community Healthcare, Others), By Distribution Channel (Hospital Pharmacy, Pharmacy Stores, Direct Tenders, Online Pharmacy), By Geography (North America, Europe, Asia-Pacific, South America, Middle East and Africa, Rest of the World) – Trends and Forecast to 2022 Dallas, TX, November 10, 2016 --( Request for sample pages: http://databridgemarketresearch.com/reports/global-drug-delivery-devices-market/ On the basis of product type the global drug delivery devices market is segmented into oral, injectable, topical, pulmonary, nasal, ocular, implantable and transmucosal. Oral drugs are further sub segmented into solid drug, semi-solid drug and liquid drug. The Pulmonary drug delivery segment is further sub segmented into metered dose inhalers (MDI), dry powder inhalers (DPI) and nebulizers. Topical drug delivery segment is further sub segmented based on form into liquid, semi-solid, solid and transdermal. Based on the distribution channel the market is segmented into hospital pharmacies, pharmacy stores, direct tenders and online pharmacy. On the basis of end-users the global drug delivery devices market is segmented into hospitals, over the counter, clinics, home healthcare, community healthcare, and others. Based on geography the market is segmented into North America, Europe, Asia-Pacific, South America and rest of the world. The report of this market shares countries such as U.S. Canada, Mexico, Germany, France, U.K., Belgium, Switzerland, Belgium, Turkey, Japan, China, Singapore, Brazil, India, Russia, South Africa. The report includes market shares of global drug delivery devices market for North America, Europe and Asia Pacific. Read more: http://databridgemarketresearch.com/reports/global-drug-delivery-devices-market/ The key players operating in this market are Bayer AG, Johnson & Johnson, Novartis AG, Pfizer, Inc., F. Hoffmann-La Roche AG, GlaxoSmithKline plc., Merck & Co., Sanofi, Antares Pharma, 3M, Becton Dickinson and Company, Nemera, Cima Labs, Inc., Dali Medical Devices, Alkermes, Foamis, Ypsomed, Skyepharma AG, Valeant Pharmaceuticals DSM Biomedical and Catalent, Inc. among others. About Data Bridge Market Research: Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process. Dallas, TX, November 10, 2016 --( PR.com )-- The Global Drug Delivery Devices Market is segmented on the basis of product type, distribution channel, end-user and geography.Request for sample pages: http://databridgemarketresearch.com/reports/global-drug-delivery-devices-market/On the basis of product type the global drug delivery devices market is segmented into oral, injectable, topical, pulmonary, nasal, ocular, implantable and transmucosal. Oral drugs are further sub segmented into solid drug, semi-solid drug and liquid drug. The Pulmonary drug delivery segment is further sub segmented into metered dose inhalers (MDI), dry powder inhalers (DPI) and nebulizers. Topical drug delivery segment is further sub segmented based on form into liquid, semi-solid, solid and transdermal.Based on the distribution channel the market is segmented into hospital pharmacies, pharmacy stores, direct tenders and online pharmacy.On the basis of end-users the global drug delivery devices market is segmented into hospitals, over the counter, clinics, home healthcare, community healthcare, and others.Based on geography the market is segmented into North America, Europe, Asia-Pacific, South America and rest of the world. The report of this market shares countries such as U.S. Canada, Mexico, Germany, France, U.K., Belgium, Switzerland, Belgium, Turkey, Japan, China, Singapore, Brazil, India, Russia, South Africa. The report includes market shares of global drug delivery devices market for North America, Europe and Asia Pacific.Read more: http://databridgemarketresearch.com/reports/global-drug-delivery-devices-market/The key players operating in this market are Bayer AG, Johnson & Johnson, Novartis AG, Pfizer, Inc., F. Hoffmann-La Roche AG, GlaxoSmithKline plc., Merck & Co., Sanofi, Antares Pharma, 3M, Becton Dickinson and Company, Nemera, Cima Labs, Inc., Dali Medical Devices, Alkermes, Foamis, Ypsomed, Skyepharma AG, Valeant Pharmaceuticals DSM Biomedical and Catalent, Inc. among others.About Data Bridge Market Research:Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process. Click here to view the list of recent Press Releases from Data Bridge Market Research


Wildschut E.D.,Sophia Childrens Hospital | Ahsman M.J.,Hospital Pharmacy | Allegaert K.,University Hospitals | Mathot R.A.A.,Hospital Pharmacy | Tibboel D.,Sophia Childrens Hospital
Intensive Care Medicine | Year: 2010

Purpose: The aim of this in vitro study was to evaluate potential determinants of drug loss in different ECMO circuits. Methods: Midazolam, morphine, fentanyl, paracetamol, cefazolin, meropenem and vancomycin were injected into three neonatal roller pump, two paediatric roller pump and two clinically used neonatal roller pump circuits, all with a silicone membrane, and two neonatal centrifugal pump circuits with polypropylene hollow-fibre membranes. Serial blood samples were taken from a post-oxygenator site. Drug recovery was calculated as the ratio between the determined and the theoretical maximum concentration. The latter was obtained by dividing dose by theoretical circuit volume. Results: Average drug recoveries at 180 min in three neonatal silicone membrane roller pump circuits were midazolam 0.62%, morphine 23.9%, fentanyl 0.35%, paracetamol 34.0%, cefazolin 84.3%, meropenem 82.9% and vancomycin 67.8%. There was a significant correlation between the lipophilicity of the drug expressed as log P and the extent of drug absorption, p < 0.001. The recovery of midazolam and fentanyl in centrifugal pump circuits with hollow-fibre membrane oxygenator was significantly higher compared to neonatal roller pump circuits with silicone membranes: midazolam 63.4 versus 0.62%, fentanyl 33.8 versus 0.35%, p < 0.001. Oxygenator size and used circuits do not significantly affect drug losses. Conclusions: Significant absorption of drugs occurs in the ECMO circuit, correlating with increased lipophilicity of the drug. Centrifugal pump circuits with hollow-fibre membrane oxygenators show less absorption for all drugs, most pronounced for lipophilic drugs. These results suggest that pharmacokinetics and hence optimal doses of these drugs may be altered during ECMO.


Minguez-Sanz M.-P.,University of Valencia | Salort-Llorca C.,Hospital Pharmacy | Silvestre-Donat F.-J.,University of Valencia
Medicina Oral, Patologia Oral y Cirugia Bucal | Year: 2011

Introduction: Burning mouth syndrome (BMS) is characterized by an oral burning sensation in the absence of any organic disorders of the oral cavity. Although the cause of BMS is not known, a complex association of biological and psychological factors has been identified, suggesting the existence of a multifactorial etiology. Material and Method: A PubMed/Medline search was used to identify articles describing the different hypotheses regarding the etiology of BMS, as well as the psychological and anatomical data upon which such hypotheses are fundamented. Results: A review and update was made of the different hypotheses relating to the etiology of BMS (psychogenic factors, hormone disorders, neuropathic alterations, oral phantom pain, neuroplasticity and neuroinflammation), with a view to globally establishing possible relationships among them. Conclusions: In-depth investigation is needed to clarify the etiopathogenic mechanisms of BMS and its triggering factors, in order to develop effective and individualized management strategies that can be extended to patients in each different BMS subgroup. © Medicina Oral.


Tartarone A.,Centro Of Riferimento Oncologico Della Basilicata | Lerose R.,Hospital Pharmacy
Therapeutic Advances in Respiratory Disease | Year: 2015

The discovery of epidermal growth factor receptor activating mutations (EGFR Mut+) has determined a paradigm shift in the treatment of non-small cell lung cancer (NSCLC). In several phase III studies, patients with NSCLC EGFR Mut+ achieved a significantly better progression-free survival when treated with a first- (gefitinib, erlotinib) or second-generation (afatinib) EGFR tyrosine kinase inhibitor (TKI) compared with standard chemotherapy. However, despite these impressive results, most patients with NSCLC EGFR Mut+ develop acquired resistance to TKIs. This review will discuss both the mechanisms of resistance to TKIs and the therapeutic strategies to overcome resistance, including emerging data on third-generation TKIs. © The Author(s), 2015.


Tartarone A.,Centro Of Riferimento Oncologico Della Basilicata | Lerose R.,Hospital Pharmacy
Therapeutic Drug Monitoring | Year: 2010

Toxic epidermal necrolysis (TEN) and Stevens-Johnson syndrome (SJS) are rare but severe cutaneous adverse reactions related to a variety of medications. Although rare, SJS and TEN have a significant impact on public health because of high mortality. Also, if the SJS/TEN physiopathology is still unclear, a specific immune response to one or more drugs is involved, constituting a form of delayed-type hypersensitivity. Patients with SJS/TEN are often critically ill; therefore, they must be admitted to hospitals capable of delivering critical care. Currently, no treatment modality has been established as standard for these patients; therefore, therapy is primarily supportive and symptomatic and involves a multidisciplinary approach. © 2010 by Lippincott Williams & Wilkins.


DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Radiodermititis Market: By Product type (Topical, Oral Medication and Dressings), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy Store, and Online Store) & By Region-Forecast (2016-2021)" report to their offering. This report identifies the global radiodermititis market size in for the year 2014-2016, and forecast of the same for year 2021. It also highlights the market drivers, restraints, growth indicators, challenges, and other key aspects with respect to global radiodermititis market. Geographically Asia-Pacific dominated radiodermititis market driven by best in the developing healthcare infrastructure, increasing awareness, increasing cancer patients and growing spending by the citizens towards healthcare expenditure. Asia-Pacific was followed by Europe and North America as second and third largest market for radiodermititis market. Asia Pacific is projected to have fastest growth, owing to rapidly increasing healthcare infrastructure, increased spending, government initiatives and increasing awareness amongst population, and growing medical tourism industry in developing nations such as China, and India in this region. Some of the major companies' profiles in detail are as follows: For more information about this report visit http://www.researchandmarkets.com/research/lc94vg/radiodermititis

Loading Hospital Pharmacy collaborators
Loading Hospital Pharmacy collaborators